Antiparasitic Drugs in Stage IV Cancer: 6-Patient Case Series (Integrative Medicine, 2026)
A 2026 case series in Integrative Medicine describes 6 stage IV cancer patients who showed prolonged survival after AMA-guided antiparasitic protocols including ivermectin and mebendazole.
By Sanare Lab · August 6, 2026 · 5 min read
A 2026 case series published in Integrative Medicine reports that six patients with stage IV cancers — including glioblastoma, lung, breast, prostate, and multiple myeloma — showed prolonged survival and, in some cases, tumour regression after receiving antiparasitic drug protocols (ivermectin, mebendazole, praziquantel, niclosamide) guided by electroacupuncture-based assessment. One patient achieved complete remission at 30+ months. These are preliminary, uncontrolled observations and do not constitute proof of efficacy.
A small but striking case series from Palo Alto, California, published in Integrative Medicine (June 2026) describes six patients with advanced stage IV cancers who received antiparasitic drug combinations — including ivermectin and mebendazole — selected using a bioelectrical assessment method called Acupuncture Meridian Assessment (AMA). All six patients survived beyond their expected conventional prognosis, and several showed objective tumour responses.
The study was authored by Guilford FT and Yu S from Your Energy Systems (Palo Alto, CA) and covers patients treated between 2011 and 2022. While the methodology is unconventional and the sample size is very small, the reported outcomes are notable: a breast cancer patient achieved complete remission (30+ months disease-free), a multiple myeloma patient has survived 14 years with normalised biomarkers, and a lung cancer patient has been disease-free for 10 years. No serious adverse events were reported.
The authors propose that antiparasitic drugs may inhibit the Wnt/β-catenin signalling pathway, which is frequently dysregulated in cancer cells. AMA — a modification of electroacupuncture according to Voll — was used to guide drug selection for each patient. The authors acknowledge that these are preliminary findings requiring controlled study.
Study Overview
The case series was published in Integrative Medicine (Encinitas, CA), June 2026, Vol. 25(3):27–33. It retrospectively describes six patients with stage IV cancers who underwent AMA-guided antiparasitic and antifungal therapy between 2011 and 2022. The primary outcomes assessed were overall survival and disease progression relative to expected conventional prognosis.
| Parameter | Detail |
|---|---|
| Study type | Retrospective case series (n=6) |
| Cancer types | Breast, lung, prostate, glioblastoma (×2), multiple myeloma |
| Stage | Stage IV (all patients) |
| Treatment period | 2011–2022 |
| Drugs used | Ivermectin, mebendazole, praziquantel, niclosamide, antifungals |
| Drug selection method | Acupuncture Meridian Assessment (AMA) |
| Published | June 2026 — Integrative Medicine (Encinitas, CA) |
| PMCID | PMC13377776 |
Patient Outcomes
The authors report the following outcomes for each of the six patients:
| Cancer Type | Reported Outcome |
|---|---|
| Breast cancer (stage IV) | Complete remission — 30+ months disease-free |
| Multiple myeloma | Surviving 14 years with normalised biomarkers |
| Lung cancer (stage IV) | Surviving 10 years post-diagnosis with negative imaging |
| Glioblastoma (patient 1) | Tumour regression, extended survival; died from head injury (fall) in 2025 |
| Glioblastoma (patient 2) | Tumour regression with extended survival (ongoing) |
| Prostate cancer (stage IV) | Surviving; PSA reduced from 32 to 0.3 |
No serious adverse events were reported across all six patients. The authors note that dental infections were addressed concurrently in all cases, which they consider potentially relevant to outcomes.
Antiparasitic Drugs Used
Drug selection was individualised for each patient based on AMA readings. The antiparasitic agents used across the cohort included:
- Ivermectin — antiparasitic with emerging evidence of Wnt/β-catenin pathway inhibition in cancer cells
- Mebendazole — benzimidazole anthelmintic with documented anti-tubulin and anti-angiogenic effects in preclinical cancer models
- Praziquantel — antiparasitic used for schistosomiasis; some preclinical anticancer data
- Niclosamide — anthelmintic with documented Wnt/β-catenin and STAT3 inhibition in cancer research
- Antifungals — specific agents not named in the abstract
The proposed mechanism is inhibition of the Wnt/β-catenin signalling pathway, which drives proliferation and survival in many cancer types. However, the authors acknowledge this mechanistic rationale is theoretical in the context of this case series.
Evidence Level and Limitations
This is a retrospective, uncontrolled case series of six patients — the lowest tier of clinical evidence. Key limitations include:
- No control group: it is impossible to determine whether outcomes were due to the antiparasitic drugs, concurrent conventional treatment, patient selection, or other factors.
- Very small sample (n=6): results cannot be generalised to the broader cancer population.
- Unconventional drug selection method: AMA (electroacupuncture-based assessment) is not a validated clinical tool; its role in drug selection is not evidence-based.
- Retrospective design: data were collected after the fact, introducing recall and selection bias.
- Long treatment period (2011–2022): concurrent advances in conventional oncology may have contributed to outcomes.
Overall evidence level: Hypothesis-generating only — these cases are interesting but do not constitute evidence that antiparasitic drugs caused the observed outcomes.
For background, see our guide to the Joe Tippens protocol.
We cover this in more depth in our article on the Care Oncology (COC) protocol.
For the fuller picture, read our deep dive into the ISOM metabolic protocol.
Plan the numbers in our interactive dosing workspace.
Frequently Asked Questions
Can ivermectin or mebendazole cure stage IV cancer?
There is no clinical trial evidence that ivermectin or mebendazole cure stage IV cancer. This case series describes six patients with unusually good outcomes, but without a control group it is impossible to attribute those outcomes to the antiparasitic drugs. Patients should not replace standard oncology care with antiparasitic protocols.
What is Acupuncture Meridian Assessment (AMA)?
AMA is a modification of electroacupuncture according to Voll — a technique that measures electrical conductance at acupuncture points to guide therapeutic decisions. It is not a validated clinical diagnostic tool and is not accepted by mainstream oncology. Its use in this study to select antiparasitic drugs is experimental.
Why are these results interesting despite the limitations?
All six patients with stage IV cancers survived beyond their expected conventional prognosis, and several showed objective responses (tumour regression, normalised biomarkers). While the study cannot prove causation, it adds to a growing body of case reports and small studies suggesting antiparasitic drugs may have anticancer activity worth investigating in controlled trials.
Is it safe to take ivermectin or mebendazole alongside cancer treatment?
Both drugs have established safety profiles at standard doses, but interactions with chemotherapy and other oncology drugs are possible. Any use of these agents alongside cancer treatment should be discussed with and supervised by an oncologist.
A 2026 case series in Integrative Medicine described six people with stage IV cancer, including glioblastoma, lung, breast, prostate, and multiple myeloma, who received antiparasitic drug combinations such as ivermectin and mebendazole, guided by Acupuncture Meridian Assessment, an electroacupuncture-based testing method. All lived longer than expected, and some had tumours shrink; one breast cancer patient had complete remission for more than 30 months. But this was tiny, retrospective, and uncontrolled, so it does not prove the drugs worked or offer an available cancer treatment.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested
6 / 12 / 18 mg — 100 tablets
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Guilford FT, Yu S. Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients. Integr Med (Encinitas). 2026 Jun;25(3):27–33. PMID: 42491797. PMCID: PMC13377776.
Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. The case series described is preliminary, uncontrolled, and cannot establish that antiparasitic drugs caused the reported outcomes. Do not use this information to make decisions about cancer treatment. Always consult a qualified healthcare professional before making any changes to your treatment plan.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.